Should We Combine Antiplatelet Therapy with Oral Factor Xa Inhibitors? - Dominick Angiolillo, MD, PhD, FSCAI

↳ This is a section part of Moment: CRT 2016 Coronary - The Oral Factor Xa Inhibitor Controversy

Add this Moment to your Passport

Learn from this moment and keep it forever.
add to passport
$12.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Should We Combine Antiplatelet Therapy with Oral Factor Xa Inhibitors? presented by Dominick Angiolillo, MD, PhD, FSCAI at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.
add to passport
$12.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Interventional Cardiologists
  • Interventional Fellows

Session Name: The Oral Factor Xa Inhibitor Controversy

Track: Coronary

Learning Objectives

  • Update in advances in ACS & AMI Management

Other Components in this Moment

Overview
Oral Anticoagulants for Atrial Fibrillation: Is There a Winner? - C. Michael Gibson, MD
Dabigatran: Are There Any Concerns? - Neal Kleiman, MD, FSCAI
Should We Combine Antiplatelet Therapy with Oral Factor Xa Inhibitors? - Dominick Angiolillo, MD, PhD, FSCAI
Rivaroxaban in Patients with ACS: Do the Data Provide Support? - C. Michael Gibson, MD
What Did We Learn from the WOEST Studies and Protocols? Are We Ready to Drop Aspirin From Triple Therapy? - Sunil Rao, MD, FSCAI
Is RNA Aptamer Technology Dead? - A. Michael Lincoff, MD
Loading Simple Education